These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 21631929)

  • 1. No relevant cardiac, pharmacokinetic or safety interactions between roflumilast and inhaled formoterol in healthy subjects: an open-label, randomised, actively controlled study.
    de Mey C; Nassr N; Lahu G
    BMC Clin Pharmacol; 2011 Jun; 11():7. PubMed ID: 21631929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β2-agonist fixed-dose combination: RE(2)SPOND rationale and study design.
    Rennard SI; Martinez FJ; Rabe KF; Sethi S; Pizzichini E; McIvor A; Siddiqui S; Anzueto A; Zhu H
    Int J Chron Obstruct Pulmon Dis; 2016; 11():1921-8. PubMed ID: 27574416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Roflumilast, a once-daily oral phosphodiesterase 4 inhibitor, lacks relevant pharmacokinetic interactions with inhaled salbutamol when co-administered in healthy subjects.
    Bethke TD; Giessmann T; Westphal K; Weinbrenner A; Hauns B; Hauschke D; David M; Lahu G; Zech K; Hermann R; Siegmund W
    Int J Clin Pharmacol Ther; 2006 Nov; 44(11):572-9. PubMed ID: 17176624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of pharmacokinetic and pharmacodynamic interactions of roflumilast with (R, S)-warfarin in healthy adult subjects.
    McCracken N; Lahu G; Bethke TD
    Int J Clin Pharmacol Ther; 2011 Jun; 49(6):388-96. PubMed ID: 21612746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Absence of pharmacokinetic interaction between roflumilast and digoxin in healthy adults.
    Eckermann G; Lahu G; Nassr N; Bethke TD
    J Clin Pharmacol; 2012 Feb; 52(2):251-7. PubMed ID: 21257799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The oral, once-daily phosphodiesterase 4 inhibitor roflumilast lacks relevant pharmacokinetic interactions with inhaled budesonide.
    Hermann R; Siegmund W; Giessmann T; Westphal K; Weinbrenner A; Hauns B; Reutter F; Lahu G; Zech K; Bethke TD
    J Clin Pharmacol; 2007 Aug; 47(8):1005-13. PubMed ID: 17660483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of steady-state enoxacin on single-dose pharmacokinetics of roflumilast and roflumilast N-oxide.
    Lahu G; Nassr N; Herzog R; Elmlinger M; Ruth P; Hinder M; Huennemeyer A
    J Clin Pharmacol; 2011 Apr; 51(4):586-93. PubMed ID: 20466871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Study investigating pharmacokinetic interaction between theophylline and roflumilast in healthy adults.
    Böhmer G; Gleiter CH; Hünnemeyer A; Lahu G; Bethke TD
    Int J Clin Pharmacol Ther; 2011 Jul; 49(7):451-60. PubMed ID: 21726496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The targeted oral, once-daily phosphodiesterase 4 inhibitor roflumilast and the leukotriene receptor antagonist montelukast do not exhibit significant pharmacokinetic interactions.
    Böhmer GM; Nassr N; Wenger M; Hünnemeyer A; Lahu G; Templin S; Gleiter CH; Hermann R
    J Clin Pharmacol; 2009 Apr; 49(4):389-97. PubMed ID: 19318692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of renal impairment on the pharmacokinetics of oral roflumilast: an open-label, parallel-group, single-center study.
    Bethke TD; Hartmann M; Hünnemeyer A; Lahu G; Gleiter CH
    Int J Clin Pharmacol Ther; 2011 Aug; 49(8):491-9. PubMed ID: 21781649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacokinetic modelling of roflumilast and roflumilast N-oxide by total phosphodiesterase-4 inhibitory activity and development of a population pharmacodynamic-adverse event model.
    Lahu G; Hünnemeyer A; Diletti E; Elmlinger M; Ruth P; Zech K; McCracken N; Facius A
    Clin Pharmacokinet; 2010 Sep; 49(9):589-606. PubMed ID: 20690782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and tolerability of formoterol in healthy volunteers after a single high dose of Foradil dry powder inhalation via Aerolizer.
    Lecaillon JB; Kaiser G; Palmisano M; Morgan J; Della Cioppa G
    Eur J Clin Pharmacol; 1999 Apr; 55(2):131-8. PubMed ID: 10335908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-inflammatory effects of roflumilast in chronic obstructive pulmonary disease (ROBERT): a 16-week, randomised, placebo-controlled trial.
    Rabe KF; Watz H; Baraldo S; Pedersen F; Biondini D; Bagul N; Hanauer G; Göhring UM; Purkayastha D; Román J; Alagappan VKT; Saetta M
    Lancet Respir Med; 2018 Nov; 6(11):827-836. PubMed ID: 30224319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease.
    Rabe KF
    Br J Pharmacol; 2011 May; 163(1):53-67. PubMed ID: 21232047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial.
    Martinez FJ; Calverley PM; Goehring UM; Brose M; Fabbri LM; Rabe KF
    Lancet; 2015 Mar; 385(9971):857-66. PubMed ID: 25684586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Roflumilast--a phosphodiesterase-4 inhibitor licensed for add-on therapy in severe COPD.
    Taegtmeyer AB; Leuppi JD; Kullak-Ublick GA
    Swiss Med Wkly; 2012; 142():w13628. PubMed ID: 22833385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of repeated dose of erythromycin on the pharmacokinetics of roflumilast and roflumilast N-oxide.
    Lahu G; Huennemeyer A; Herzog R; McCracken N; Hermann R; Elmlinger M; Zech K
    Int J Clin Pharmacol Ther; 2009 Apr; 47(4):236-45. PubMed ID: 19356389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic and Pharmacodynamic Modelling to Characterize the Tolerability of Alternative Up-Titration Regimens of Roflumilast in Patients with Chronic Obstructive Pulmonary Disease.
    Facius A; Marostica E; Gardiner P; Watz H; Lahu G
    Clin Pharmacokinet; 2018 Aug; 57(8):1029-1038. PubMed ID: 29797235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of single and repeated doses of ketoconazole on the pharmacokinetics of roflumilast and roflumilast N-oxide.
    Lahu G; Huennemeyer A; von Richter O; Hermann R; Herzog R; McCracken N; Zech K
    J Clin Pharmacol; 2008 Nov; 48(11):1339-49. PubMed ID: 18757786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Roflumilast Cream Improves Signs and Symptoms of Plaque Psoriasis: Results from a Phase 1/2a Randomized, Controlled Study.
    Papp KA; Gooderham M; Droege M; Merritt C; Osborne DW; Berk DR; Thurston AW; Smith VH; Welgus H
    J Drugs Dermatol; 2020 Aug; 19(8):734-740. PubMed ID: 32845114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.